Polaryx Therapeutics Inc (PLYX)
Polaryx Therapeutics Inc. is a clinical-stage biotechnology company focused on developing disease-modifying treatments for rare and pediatric lysosomal storage disorders in the United States. The company’s pipeline includes PLX-100, an orally administered combination therapy in preclinical development; PLX-200, a repurposed oral small-molecule candidate for lysosomal storage disorders; PLX-300, another preclinical oral combination therapy; and PLX-400, a preclinical gene therapy program. Founded in 2014, Polaryx Therapeutics is based in Paramus, New Jersey, and its common stock trades on the NASDAQ under the ticker PLYX.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-PLYX
|
$1.42
|
-18.3% Downside
|
Overvalued
|
$7.50
|
331.0% Upside
|
Bargain
|
Weak
|
0.0%
|
December 2, 2026
|
7.9x
|
86.732 M
|
75.19 M
|
0.0%
|
14.4%
|
49.0
|
84.8%
|
